Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 968-974

  Gumbo, Tawanda ^a,b   Drusano, George L ^a   Liu, Weiguo ^a   Kulawy, Robert W ^a   Fregeau, Christine ^a   Hsu, Vasha ^a   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDA GLABRATA; CANDIDEMIA; COLONY FORMING UNIT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG HALF LIFE; FUNGUS GROWTH; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; LIPOPROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; NEUTROPENIA; PEPTIDES, CYCLIC;

EID: 33847652168     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01337-06     Document Type: Article

References (41)

1. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automated Control 19:716-723.
2. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
3. Ambrose, P. G., S. J. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
4. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
5. Andes, D., A. Forrest, A. Lepak, J. Nett, K. Marchillo, and L. Lincoln. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chemother. 50:2374-2383.
6. Andes, D., K. Marchillo, J. Lowther, A. Bryskier, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1187-1192.
7. Bertagnolio, S., D. K. de Gaetano, E. Tacconelli, G. Scoppettuolo, B. Posteraro, G. Fadda, R. Cauda, and M. Tumbarello. 2004. Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors and predictors of outcome. J. Chemother. 16:172-178.
8. Betts, R., A. Glasmacher, J. Maertens, G. Maschmeyer, J. A. Vazquez, H. Teppler, A. Taylor, R. Lupinacci, C. Sable, and N. Kartsonis. 2006. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106:466-473.
9. Bodey, G. P., M. Mardani, H. A. Hanna, M. Boktour, J. Abbas, E. Girgawy, R. Y. Hachem, D. P. Kontoyiannis, and I. I. Raad. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:380-385.
10. 9a. Buell, D., L. Kovanda, T. Drake, and C. Frisco. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-79.
11. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
12. Clinical and Laboratory Standards Institute. 1997. Clinical and Laboratory Standards Institute reference method for dilution antifungal susceptibility testing of yeast; approved standards. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
14. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
15. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
16. Eagle, H., R. Fleischman, and A. D. Musselman. 1950. Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. Am. J. Med. 9:280-299.
17. Fatkenheuer, G., D. Buchheidt, O. A. Cornely, H. G. Fuhr, M. Karthaus, J. Kisro, M. Leithauser, H. Salwender, T. Sudhoff, H. Szelenyi, and F. Weissinger. 2003. Central venous catheter (CVC)-related infections in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 82(Suppl. 2):S149-S157.
18. Gumbo, T., R. F. Chemaly, C. M. Isada, G. S. Hall, and S. M. Gordon. 2002. Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon. Scand. J. Infect. Dis. 34:817-818.
19. Gumbo, T., G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50:3695-3700.
20. Gumbo, T., C. M. Isada, G. Hall, M. T. Karafa, and S. M. Gordon. 1999. Candida glabrata fungemia. Clinical features of 139 patients. Medicine (Baltimore) 78:220-227.
21. 19a. Gumbo, T., W. Liu, C. Fregeau, V. Hsu, G. L. Drusano, and A. Louie. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-0310a.
22. 19b. Gumbo, T., A. Louie, W. Liu, M. R. Deziel, M. Drusano, L. Turner, C. Fregeau, D. Brown, and G. L. Drusano. 2004. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1875.
23. Hiemenz, J., P. Cagnoni, D. Simpson, S. Devine, N. Chao, J. Keirns, W. Lau, D. Facklam, and D. Buell. 2005. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49:1331-1336.
24. Kartsonis, N., J. Killar, L. Mixson, C. M. Hoe, C. Sable, K. Bartizal, and M. Motyl. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. 49:3616-3623.
25. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
26. Leary, R., R. Jellife, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. IEEE Computer Society, Bethesda, MD.
27. Louie, A., M. Deziel, W. Liu, M. F. Drusano, T. Gumbo, and G. L. Drusano. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
28. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
29. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, non-comparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661.
30. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
31. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
32. Pfaller, M. A., D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and B. P. Goldstein. 2005. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49:4795-4797.
33. Polderman, K. H., and A. R. Girbes. 2002. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med. 28:1-17.
34. Polderman, K. H., and A. R. Girbes. 2002. Central venous catheter use. Part 1: infectious complications. Intensive Care Med. 28:18-28.
35. 31a. Reboli, A., C. Rotstein, P. G. Pappas, J. Schranz, D. Krause, and T. Walsh. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. abstr. M-718.
36. Sirohi, B., R. L. Powles, R. Chopra, N. Russell, J. L. Byrne, H. G. Prentice, M. Potter, and S. Koblinger. 2006. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 38:47-51.
37. Tacconelli, E., M. Tumbarello, D. K. de Gaetano, S. Bertagnolio, M. Pittiruti, F. Leone, G. Morace, and R. Cauda. 2000. Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. J. Hosp. Infect. 44:186-192.
38. Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.
39. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
40. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.
41. Yamato, Y., H. Kanedo, T. Hashimoto, M. Katashima, K. Ishibashi, A. Kawamura, M. Terakawa, and A. Kagayama. 2002. Pharmacokinetics of the antifungal drug micafungin in mice, rats, and dogs and in its in vitro protein binding and distribution to blood cells. Jpn. J. Chemother. 50:74-79.